Table 2.
Data input for the calculations
| Parameter | Caspofungin group | Liposomal amphotericin B groupa |
|---|---|---|
| Nephrotoxicity riskb | 2.6%c (95% CI 1.55–4.24; n = 547) | 11.5%c (95% CI 9.05–14.53; n = 522) |
| Absolute risk differencec | −8.9% (95% CI 5.9–12.0) | |
| Treatment days per stayc | 13 | 12.5 |
| Drug cost according to official German price list (2007, incl. 19% VAT) | ||
| Per bottle, 70 mg | €799.57d | – |
| Per bottle, 50 mg | €630.68e | €209.43 |
| Per day of treatment | (see above) | €879.61 |
| Total | €8,368 | €10,995 |
| Drug cost according to high-user hospital pharmacy drug acquisition cost (2007, incl. 19% VAT) | ||
| Per bottle, 70 mg | €559.30 (day 1) | – |
| Per bottle, 50 mg | €428.40 (days 2–13) | €96.99 |
| Per day of treatment | (see above) | €407.34 |
| Total | €5,700 | €5,092 |
| Supplementary reimbursement (Zusatzentgelt, 2007) | ||
| Treatment-related code (mg range applicable) | 39.12 (600 mg–<700 mg) | 43.16 (2,150 mg–<3,150 mg) |
| Supplementary reimbursement (ZE) | €5,151 | €4,745 |
ZE Zusatzentgelt, a treatment-related extra reimbursement scheme that is paid besides DRG for medicines and devices that cannot be allocated to a single DRG. In 2007, L-AmB as well as caspofungin are covered under this scheme.
aLiposomal amphotericin B, 3 mg per kg bodyweight per day, 70-kg patient
bCaspofungin vs liposomal amphotericin B
cData from the original publication
dDay 1
eDays 2–13